Risk of IS and MI in relation to VWF and ADAMTS13 plasma levels
. | Controls, n . | IS . | MI . | ||||
---|---|---|---|---|---|---|---|
Cases, n . | OR1 (95% CI) . | OR2 (95% CI) . | Cases, n . | OR1 (95% CI) . | OR2 (95% CI) . | ||
VWF Q1 | 156 | 13 | 1 (ref) | 1 (ref) | 20 | 1 (ref) | 1 (ref) |
VWF Q2 | 157 | 22 | 1.4 (0.7-3.1) | 1.6 (0.7-3.6) | 35 | 1.6 (0.9-3.0) | 1.7 (0.9-3.4) |
VWF Q3 | 157 | 50 | 3.8 (1.9-7.6) | 4.2 (2.0-9.0) | 60 | 2.5 (1.4-4.5) | 3.1 (1.6-5.9) |
VWF Q4 | 156 | 82 | 5.9 (3.0-11.7) | 6.7 (3.2-13.8) | 87 | 3.7 (2.1-6.5) | 4.2 (2.2-8.0) |
ADAMTS13 Q1 | 156 | 61 | 3.1 (1.8-5.5) | 3.1 (1.6-5.8) | 63 | 1.8 (1.1-3.0) | 1.4 (0.8-2.4) |
ADAMTS13 Q2 | 157 | 45 | 2.4 (1.4-4.4) | 3.0 (1.6-5.7) | 50 | 1.2 (0.8-2.0) | 0.9 (0.5-1.6) |
ADAMTS13 Q3 | 157 | 33 | 1.5 (0.8-2.7) | 1.7 (0.9-3.3) | 44 | 1.0 (0.6-1.7) | 0.8 (0.5-1.5) |
ADAMTS13 Q4 | 156 | 28 | 1 (ref) | 1 (ref) | 45 | 1 (ref) | 1 (ref) |
. | Controls, n . | IS . | MI . | ||||
---|---|---|---|---|---|---|---|
Cases, n . | OR1 (95% CI) . | OR2 (95% CI) . | Cases, n . | OR1 (95% CI) . | OR2 (95% CI) . | ||
VWF Q1 | 156 | 13 | 1 (ref) | 1 (ref) | 20 | 1 (ref) | 1 (ref) |
VWF Q2 | 157 | 22 | 1.4 (0.7-3.1) | 1.6 (0.7-3.6) | 35 | 1.6 (0.9-3.0) | 1.7 (0.9-3.4) |
VWF Q3 | 157 | 50 | 3.8 (1.9-7.6) | 4.2 (2.0-9.0) | 60 | 2.5 (1.4-4.5) | 3.1 (1.6-5.9) |
VWF Q4 | 156 | 82 | 5.9 (3.0-11.7) | 6.7 (3.2-13.8) | 87 | 3.7 (2.1-6.5) | 4.2 (2.2-8.0) |
ADAMTS13 Q1 | 156 | 61 | 3.1 (1.8-5.5) | 3.1 (1.6-5.8) | 63 | 1.8 (1.1-3.0) | 1.4 (0.8-2.4) |
ADAMTS13 Q2 | 157 | 45 | 2.4 (1.4-4.4) | 3.0 (1.6-5.7) | 50 | 1.2 (0.8-2.0) | 0.9 (0.5-1.6) |
ADAMTS13 Q3 | 157 | 33 | 1.5 (0.8-2.7) | 1.7 (0.9-3.3) | 44 | 1.0 (0.6-1.7) | 0.8 (0.5-1.5) |
ADAMTS13 Q4 | 156 | 28 | 1 (ref) | 1 (ref) | 45 | 1 (ref) | 1 (ref) |
ORs were calculated by logistic regression and were adjusted for age, year of event/index year, and area of residence. OR2 values were also adjusted for hypercholesterolemia, hypertension, diabetes mellitus, and smoking.
Q indicates quartile; and ref, reference.